Liisa Bayko

Work Rating Distribution Performance Price Targets & Ratings Chart

Analyst Liisa Bayko works at EVERCORE and is focused on the Healthcare sector with 248 price targets and ratings documented since 2008 spanning on 19 stocks. Analyst's average stock valuation to be materialised ratio is 53.09% with an average time for price targets to be met of 197 days.

Most recent stock forecast was given on ALT, Altimmune, Inc at 18-Jan-2023.

Liisa Bayko best performing recommendations are on ALT (ALTIMMUNE, INC).
The best stock recommendation documented was for BCRX (BIOCRYST PHARMACEUTICALS, INC) at 7/19/2013. The price target of $3 was fulfilled within 3 days with a profit of $0.54 (21.95%) receiving and performance score of 73.17.

Average potential price target upside

of $47.28 (35.87%) on MDGL (MADRIGAL PHARMACEUTICALS, INC).
of $21.47 (22.5%) on VRTX (VERTEX PHARMACEUTICALS INCORPORATED).
of $18.45 (31.85%) on RARE (ULTRAGENYX PHARMACEUTICAL INC).

Currently, out of the existing stock ratings of Liisa Bayko - 12711 which are a Buy (80.88%), 2535 which are a Hold (16.13%), 470 which are a Sell (2.99%)